Related references
Note: Only part of the references are listed.Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair
Meredith A. Morgan et al.
CANCER RESEARCH (2010)
Targeting the checkpoint kinase Chk1 in cancer therapy
Callie Merry et al.
CELL CYCLE (2010)
In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762
James B. Mitchell et al.
CLINICAL CANCER RESEARCH (2010)
New models for cancer research: human cancer stem cell xenografts
Marta Baiocchi et al.
CURRENT OPINION IN PHARMACOLOGY (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Early Changes in Tumor Size in Patients Treated for Advanced Stage Nonsmall Cell Lung Cancer Do Not Correlate With Survival
Katherine R. Birchard et al.
CANCER (2009)
A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics
Y. H. Wang et al.
NEOPLASMA (2009)
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment
Giulia Bertolini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
N. Bucher et al.
BRITISH JOURNAL OF CANCER (2008)
Apoptosis and non-apoptotic deaths in cancer development and treatment response
Elza C. de Bruin et al.
CANCER TREATMENT REVIEWS (2008)
Keeping checkpoint kinases in line: new selective inhibitors in clinical trials
Susan Ashwell et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials
Guo-Ming Shi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from southwest oncology group Randomized trials
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
Sonya D. Zabludoff et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Identification and expansion of the tumorigenic lung cancer stem cell population
A. Eramo et al.
CELL DEATH AND DIFFERENTIATION (2008)
Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells
Maria M. Ho et al.
CANCER RESEARCH (2007)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
Identification of bronchioalveolar stem cells in normal lung and lung cancer
CFB Kim et al.
CELL (2005)
Chk1 is essential for tumor cell viability following activation of the replication checkpoint
SH Cho et al.
CELL CYCLE (2005)
Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy
SY El Sharouni et al.
BRITISH JOURNAL OF CANCER (2003)
Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways
CR Yu et al.
CANCER BIOLOGY & THERAPY (2003)
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents
Z Xiao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Chk1 and Chk2 kinases in checkpoint control and cancer
J Bartek et al.
CANCER CELL (2003)
Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation
M Gatei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Cell cycle checkpoint signaling through the ATM and ATR kinases
RT Abraham
GENES & DEVELOPMENT (2001)
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
S Matsuoka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
